SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to highly positive Phase 3 trial results for its hereditary angioedema therapy, marking a major milestone for in vivo CRISPR gene editing. While many in the community anticipate a potential short squeeze due to high short interest and the significant clinical success, others are warning of a 'sell-the-news' reaction following the stock's recent run-up.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant community excitement as investors anticipate critical clinical trial updates and a high-profile oral presentation at the upcoming Digestive Disease Week (DDW) conference. Supporters are highlighting the company's strong institutional backing and technical progress as key drivers, viewing the current market positioning as a strategic accumulation opportunity ahead of potential upcoming data catalysts.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors respond to a multi-billion dollar share buyback program and strong subscriber growth fueled by competitive service pricing, which many in the community view as a successful defensive strategy against rivals. Market participants are actively discussing the stock's stability and consistent dividends as a pivot point for defensive positioning while tracking its recent breakout to multi-year highs.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining momentum as a community-driven project fueled by active developer engagement, including consistent token airdrops and transparency regarding project milestones. Investors are closely tracking the token's ability to hold its floor following recent highs, with many in the community optimistic about its potential as a multi-day runner while they await upcoming chart integrations.

"What's Updog?" is a Community Led token.

UpDog

UpDog is experiencing a surge in community engagement and whale accumulation as long-term holders highlight its sustained presence on the Solana network. The community is actively leveraging the 'UpDog' meme to drive organic interest, drawing comparisons to other dog-themed assets while emphasizing the project's longevity and established liquidity.

RE/MAX Holdings, Inc. engages in the provision of real estate franchise services through its subsidiaries. It operates through the following segments: Real Estate, Mortgage and Marketing Funds. The Real Estate segment consists of the company’s owned and independent global franchising operations under the RE/MAX brand name and technology and data subscription for Gadberry and the First app. The Mortgage segment consists of the firm's mortgage brokerage franchising operations under the Motto Mortgage brand name and mortgage loan processing services and licensed software under the wemlo brand. The Marketing Funds segment is involved in marketing campaigns designed to build and maintain brand awareness and the development and operation of agent marketing technology. The company was founded by David L. Liniger and Gail A. Liniger in 1973 and is headquartered in Denver, CO.

RE/MAX Holdings Inc - Ordinary Shares - Class A

RE/MAX Holdings is currently at the center of market discussions as investors weigh its potential for an acquisition against broader real estate sector challenges. While some in the community are optimistic about a potential takeout and the company's long-term brand value, others remain cautious due to the competitive landscape and ongoing industry consolidation.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is attracting significant investor attention following reports that it is collaborating with OpenAI to develop AI-powered smartphone processors, a development seen as a major catalyst for the semiconductor sector. The community is actively discussing the stock's potential as an undervalued AI-at-the-edge play, with many traders debating the long-term impact of this partnership on mobile device innovation versus lingering concerns about handset market headwinds.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is currently drawing significant investor attention due to the upcoming readout of Phase 2/3 topline secondary endpoints for its lead oncology candidate, tovecimig, scheduled for early this week. The community is actively debating the potential for a positive data surprise against historical benchmarks in biliary tract cancer, while closely monitoring for any signs of institutional positioning or volatility ahead of the webcast.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing community attention as traders debate the coin's potential during the annual 'Doge Day' festivities, with sentiment split between long-term holders anticipating a breakout and skeptics focusing on consolidation patterns. The active discussion is driven by retail interest in meme coin volatility and ongoing speculation regarding future adoption or social media catalysts.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics Inc.

Oruka Therapeutics is experiencing significant market attention following positive Phase 2a results for its lead candidate ORKA-001 in treating moderate-to-severe plaque psoriasis. Investors are actively discussing the potential for clinical differentiation against established market leaders, while also debating the long-term impact of recent capital-raising activities and the company's ambitious valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Axecap Investments LLC Has $3.65 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Axecap Investments LLC decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 32.8% in the 4th quarter, according to its most recent filing with the Securities...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty analysts that are currently covering the firm, MarketBeat reports...

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 10,638,508 shares, a...

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadias...

CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?

CSLLY vs. ACAD: Which Stock Is the Better Value Option?

Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?

Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

James Kihara Sells 1,030 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,030 shares of the business's stock in a transaction on Tuesday, April 7th. The shares were sold at an average...

ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells $60,139.80 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark Schneyer sold 2,709 shares of the firm's stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $22.20, for a total value of $60,139.80. Following the completion of the sale, the...

ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Sells $22,866.00 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,030 shares of the business's stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $22.20, for a total value of $22,866.00. Following the completion of the sale...

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Current Price	$21.96
Prev Close	$22.11
Open	$22.03
Dividend Yield	0.00%
50-Day Moving Average	$22.24
Beta	0.97
Avg. Volume	1.99M
PE Ratio	9.60

52-Week High	$28.35
52-Week Low	$14.18
Market Capitalization	$3.74B
EPS (Annual)	$2.30
Price to Book	3.05
Revenue Per Employee	$1.34M

ACAD
Acadia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACAD News

ACADAcadia Pharmaceuticals Inc